Pfizer Inc (NYSE: PFE) made a promise to outdo cancer, joining its Covid vaccine-peer, Moderna Inc (NASDAQ: MRNA) in turning ...

Some proteins in the human body are easy to block with a drug; they have an obvious spot in their structure where a drug can fit, like a key in a lock. But other proteins are more difficult to target, ...

Health-care CVS Health has spent more than $88 billion in the last half-dozen years to add a major health insurer, a clinic operator and a home-visit provider to its namesake pharmacies, but the ...

With Tuesday’s announcement, Eastern North Carolina adds to its reputation for large-scale pharmaceutical manufacturing, as ...

One expert in Indiana expects to see another wave of COVID-19 infections during late spring based on past patterns.

A good chunk of your paycheck goes to medical insurance. Know your options. Prudent action and planning maximize every dollar ...

“Right now is the best time” to get all the recommended fall vaccinations, said Dr. Mandy Cohen, director of the Centers for ...

Pfizer withdrew its sickle cell disease treatment Oxbryta. Meanwhile, Senators introduce new bill to fortify health-care ...

No large pharma company has traversed this decade's ups and downs quite like Pfizer. | No large pharma company has traversed ...

Pfizer recalled Oxbryta and ended clinical trials over safety concerns, but sickle cell advocates are warning that stopping the drug abruptly could be dangerous.

Over the next three months, the agency could approve a rival to a fast-selling Pfizer heart drug, a much-debated lung cancer medicine and an addition to Vertex's dominant cystic fibrosis business.

Pfizer withdrew Oxbryta (voxelotor), a conditionally approved oral therapy for SCD, saying its benefits don't outweigh risks.